Medicines Co (MDCO.O)
17 Feb 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2015||Non-Executive Chairman of the Board|
|50||2016||President, Chief Operating Officer|
|58||2015||Chief Executive Officer, Director|
|57||2016||Chief Financial Officer, Principal Accounting Officer|
|51||2016||Executive Vice President, chief corporate development officer|
- BRIEF-Mylan signs sub-license agreement with the Medicines Patent Pool to produce and market DAKLINZA tablets to 112 countries
- BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran
- Long-lasting cholesterol lowering seen with Medicines Co drug: study
- Long-lasting cholesterol lowering seen with Medicines Co drug -study
- BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran